O. Kisker

4.3k total citations · 1 hit paper
43 papers, 3.3k citations indexed

About

O. Kisker is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, O. Kisker has authored 43 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in O. Kisker's work include Colorectal Cancer Treatments and Studies (13 papers), Angiogenesis and VEGF in Cancer (10 papers) and Cancer, Hypoxia, and Metabolism (8 papers). O. Kisker is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Angiogenesis and VEGF in Cancer (10 papers) and Cancer, Hypoxia, and Metabolism (8 papers). O. Kisker collaborates with scholars based in Germany, United States and Spain. O. Kisker's co-authors include Evelyn Flynn, Judah Folkman, Eric Van Cutsem, Μ. Rothmund, Philip J. Hogg, A. Zielke, Yves Humblet, Steven Pirie‐Shepherd, M. E. Vega-Villegas and Sabine Tejpar and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

O. Kisker

43 papers receiving 3.2k citations

Hit Papers

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After ... 2008 2026 2014 2020 2008 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
    2008 726 citations Alberto Sobrero, Joan Maurel et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Kisker Germany 28 2.0k 988 876 620 555 43 3.3k
Mark Kozloff United States 36 3.2k 1.6× 1.3k 1.3× 1.7k 1.9× 702 1.1× 612 1.1× 125 4.7k
Ilhan Celik Germany 15 2.8k 1.4× 749 0.8× 1.6k 1.9× 605 1.0× 682 1.2× 31 3.9k
Elizabeth Poplin United States 24 2.2k 1.1× 681 0.7× 1.2k 1.4× 485 0.8× 721 1.3× 80 3.2k
David Walde Canada 16 3.7k 1.8× 1.0k 1.0× 1.4k 1.6× 1.0k 1.7× 901 1.6× 22 4.8k
D. J. Richel Netherlands 18 1.6k 0.8× 725 0.7× 894 1.0× 513 0.8× 511 0.9× 38 2.6k
Susana Roselló Spain 31 2.3k 1.1× 885 0.9× 1.0k 1.1× 859 1.4× 686 1.2× 89 3.6k
Wing‐Kai Chan Taiwan 22 1.4k 0.7× 1.4k 1.4× 1.2k 1.4× 828 1.3× 307 0.6× 57 3.2k
Petr Kavan Canada 29 1.5k 0.7× 1.0k 1.0× 1.1k 1.3× 876 1.4× 390 0.7× 141 4.4k
Masao Kameyama Japan 31 1.3k 0.6× 1.3k 1.3× 1.1k 1.2× 384 0.6× 930 1.7× 158 3.4k
Henry Q. Xiong United States 18 2.8k 1.4× 1.2k 1.2× 1.3k 1.5× 1.0k 1.7× 801 1.4× 39 4.3k

Countries citing papers authored by O. Kisker

Since Specialization
Citations

This map shows the geographic impact of O. Kisker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Kisker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Kisker more than expected).

Fields of papers citing papers by O. Kisker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Kisker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Kisker. The network helps show where O. Kisker may publish in the future.

Co-authorship network of co-authors of O. Kisker

This figure shows the co-authorship network connecting the top 25 collaborators of O. Kisker. A scholar is included among the top collaborators of O. Kisker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Kisker. O. Kisker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cutsem, Eric Van, István Láng, G D’Haens, et al.. (2008). The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri. Annals of Oncology. 19. 17–17. 11 indexed citations
2.
Cutsem, Eric Van, István Láng, G D’Haens, et al.. (2008). KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Journal of Clinical Oncology. 26(15_suppl). 2–2. 281 indexed citations
3.
4.
Cutsem, Eric Van, Yves Humblet, Hans Gelderblom, et al.. (2006). Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment (Everest): Preliminary PK and efficacy data of a randomized study. Annals of Oncology. 17. 7 indexed citations
5.
6.
Sobrero, Alberto, Werner Scheithauer, Joan Maurel, et al.. (2005). Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC). Journal of Clinical Oncology. 23(16_suppl). 3580–3580. 6 indexed citations
7.
Becker, Christian M., et al.. (2003). Treatment of Human Pancreatic Cancer in Mice with Angiogenic Inhibitors. World Journal of Surgery. 27(4). 405–411. 32 indexed citations
8.
Kisker, O., Shinya Onizuka, Christian M. Becker, et al.. (2003). Vitamin D Binding Protein-Macrophage Activating Factor (DBP-maf) Inhibits Angiogenesis and Tumor Growth in Mice. Neoplasia. 5(1). 32–40. 100 indexed citations
9.
Tseng, Jennifer F., Filip Farnebo, O. Kisker, et al.. (2002). Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery. 132(5). 857–865. 35 indexed citations
10.
Pirie‐Shepherd, Steven, Karen Coffman, Donald Resnick, et al.. (2002). The Role of Angiostatin in the Spontaneous Bone and Prostate Cancers of Pet Dogs. Biochemical and Biophysical Research Communications. 292(4). 886–891. 5 indexed citations
11.
Achilles, E., Ariel Fernández, Elizabeth N. Allred, et al.. (2001). Heterogeneity of Angiogenic Activity in a Human Liposarcoma: a Proposed Mechanism for "No Take" of Human Tumors in Mice. JNCI Journal of the National Cancer Institute. 93(14). 1075–1081. 71 indexed citations
12.
Beecken, Wolf‐Dietrich, Dipak Panigrahy, Eike‐Gert Achilles, et al.. (2000). Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology. 56(3). 521–526. 21 indexed citations
13.
Lay, Angelina J., Xing‐Mai Jiang, O. Kisker, et al.. (2000). Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature. 408(6814). 869–873. 227 indexed citations
14.
Bartsch, Detlef K., Bastian Daniel, Peter Barth, et al.. (1998). K-ras Oncogene Mutations Indicate Malignancy in Cystic Tumors of the Pancreas. Annals of Surgery. 228(1). 79–86. 74 indexed citations
15.
Kisker, O., et al.. (1997). The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.. PubMed. 184(5). 487–92. 35 indexed citations
16.
Schmidt, Sabine, et al.. (1997). Reactive thymic hyperplasia following treatment of ACTH-producing tumors. Der Radiologe. 37(11). 913–917. 2 indexed citations
17.
Gerdes, Berthold, et al.. (1997). The anatomical basis of anal endosonography. Surgical Endoscopy. 11(10). 986–990. 27 indexed citations
18.
Weinel, R. J., et al.. (1996). Expression and potential role of E-cadherin in pancreatic carcinoma. International Journal of Pancreatology. 19(1). 25–30. 30 indexed citations
19.
Weinel, R. J., et al.. (1995). The α6-integrin receptor in pancreatic carcinoma. Gastroenterology. 108(2). 523–532. 44 indexed citations
20.
Bartsch, Detlef K., Douglas W. Shevlin, William S. Tung, et al.. (1995). Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes and Cancer. 14(3). 189–195. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Kozloff Breakdown of academic impact, for papers by Ilhan Celik Breakdown of academic impact, for papers by Elizabeth Poplin Breakdown of academic impact, for papers by David Walde Breakdown of academic impact, for papers by D. J. Richel Breakdown of academic impact, for papers by Susana Roselló Breakdown of academic impact, for papers by Wing‐Kai Chan Breakdown of academic impact, for papers by Petr Kavan Breakdown of academic impact, for papers by Masao Kameyama Breakdown of academic impact, for papers by Henry Q. Xiong
Rankless by CCL
2026